[The PET scan in neuro-oncology--indications, differential diagnosis and clinical application].
Results of 157 PET (positron emission tomography) studies in 102 patients with known or presumed intracranial (ic.) tumors are reviewed. In 106 studies [18F]-2-fluoro-2-deoxy-D-glucose (FDG) and in 51 cases [11C]-methionine (MET) was used as the PET tracer. CT and MRI imaging accompanied the PET studies in each case. Results of pre- and/or postoperative studies are compared. PET was concluded to have a fundamental role in the precise differential diagnosis in case of ic. space-occupying pathologies since it is capable of providing information that is not obtainable or may be equivocal based solely on CT and/or MRI investigations. However, it is also mandatory to be aware of the limits of PET.
Novák
László
L
Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Idegsebészeti Klinika, Debrecen. lnovak@jaguar.dote.hu
Emri
Miklós
M
Balkay
László
L
Galuska
László
L
Esik
Olga
O
Molnár
Péter
P
Csécsei
György
G
Trón
Lajos
L
D000293:Adolescent; D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000601:surgery; D002250:Carbon Radioisotopes; D002648:Child; D002675:Child, Preschool; D003937:Diagnosis, Differential; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D014055:Tomography, Emission-Computed / Q000379:methods / Q000592:standards; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D002250:Carbon Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18